{"product_id":"adamax-10mg-vial","title":"Adamax 10mg vial","description":"\u003cp data-end=\"576\" data-start=\"116\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"576\" data-start=\"116\"\u003e\u003cstrong data-end=\"126\" data-start=\"116\"\u003eAdamax\u003c\/strong\u003e is a \u003cstrong data-end=\"171\" data-start=\"132\"\u003esynthetic peptide analogue of Semax\u003c\/strong\u003e that is widely described as \u003cstrong data-end=\"287\" data-start=\"200\"\u003eSemax modified with the N-terminal and C-terminal “caps” used in Peptide-021 (P021)\u003c\/strong\u003e—a design strategy intended to increase \u003cstrong data-end=\"340\" data-start=\"327\"\u003estability\u003c\/strong\u003e and \u003cstrong data-end=\"361\" data-start=\"345\"\u003eCNS exposure\u003c\/strong\u003e (via lipophilic\/steric protection motifs). The sequence is commonly listed as \u003cstrong data-end=\"461\" data-start=\"440\"\u003eAc-MEHFPGP^AG-NH₂\u003c\/strong\u003e, where “^A” indicates an \u003cstrong data-end=\"519\" data-start=\"487\"\u003eadamantyl-containing residue\u003c\/strong\u003e in some notations. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"838\" data-start=\"578\"\u003e\u003cstrong data-end=\"600\" data-start=\"578\"\u003eRegulatory signal:\u003c\/strong\u003e New Zealand’s Medsafe has explicitly referenced \u003cstrong data-end=\"719\" data-start=\"649\"\u003eAdamax and Semax as ACTH analogues marketed as cognitive enhancers\u003c\/strong\u003e, in the context of proposed scheduling\/classification of “unscheduled peptides.” \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"843\" data-start=\"840\"\u003e\n\u003ch3 data-end=\"877\" data-start=\"845\"\u003e2) Chemical design rationale\u003c\/h3\u003e\n\u003ch4 data-end=\"909\" data-start=\"879\"\u003e2.1 Relationship to Semax\u003c\/h4\u003e\n\u003cp data-end=\"1255\" data-start=\"910\"\u003e\u003cstrong data-end=\"919\" data-start=\"910\"\u003eSemax\u003c\/strong\u003e itself is a synthetic peptide originally developed in Russia and widely studied in \u003cstrong data-end=\"1065\" data-start=\"1003\"\u003epreclinical neuroprotection and gene-expression modulation\u003c\/strong\u003e, including in brain ischemia models. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003cbr data-end=\"1143\" data-start=\"1140\"\u003eAdamax is positioned as a \u003cstrong data-end=\"1205\" data-start=\"1169\"\u003enext-generation Semax derivative\u003c\/strong\u003e, not a Khavinson “bioregulator” (2–4 aa) peptide.\u003c\/p\u003e\n\u003ch4 data-end=\"1306\" data-start=\"1257\"\u003e2.2 Why “adamantyl” and terminal caps matter\u003c\/h4\u003e\n\u003cp data-end=\"1364\" data-start=\"1307\"\u003eThe Adamax design is commonly described as incorporating:\u003c\/p\u003e\n\u003cul data-end=\"1745\" data-start=\"1365\"\u003e\n\u003cli data-end=\"1501\" data-start=\"1365\"\u003e\n\u003cp data-end=\"1501\" data-start=\"1367\"\u003e\u003cstrong data-end=\"1399\" data-start=\"1367\"\u003eN-terminal acetylation (Ac-)\u003c\/strong\u003e and \u003cstrong data-end=\"1435\" data-start=\"1404\"\u003eC-terminal amidation (-NH₂)\u003c\/strong\u003e to reduce exopeptidase degradation and improve peptide stability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1745\" data-start=\"1502\"\u003e\n\u003cp data-end=\"1745\" data-start=\"1504\"\u003eAn \u003cstrong data-end=\"1545\" data-start=\"1507\"\u003eadamantyl-associated motif\/residue\u003c\/strong\u003e (per sequence notation and marketplace descriptions) inspired by \u003cstrong data-end=\"1619\" data-start=\"1611\"\u003eP021\u003c\/strong\u003e, intended to increase \u003cstrong data-end=\"1659\" data-start=\"1642\"\u003elipophilicity\u003c\/strong\u003e and support \u003cstrong data-end=\"1706\" data-start=\"1672\"\u003eBBB penetration\/brain exposure\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1952\" data-start=\"1747\"\u003e\u003cem data-end=\"1763\" data-start=\"1747\"\u003eReality check:\u003c\/em\u003e while this medicinal-chemistry logic is plausible in principle, \u003cstrong data-end=\"1914\" data-start=\"1828\"\u003epublished, peer-reviewed PK\/BBB data for Adamax itself are not clearly established\u003c\/strong\u003e in widely indexed literature sources.\u003c\/p\u003e\n\u003chr data-end=\"1957\" data-start=\"1954\"\u003e\n\u003ch3 data-end=\"2054\" data-start=\"1959\"\u003e3) Molecular mechanism of action (inferred, because direct Adamax primary data are limited)\u003c\/h3\u003e\n\u003ch4 data-end=\"2090\" data-start=\"2056\"\u003e3.1 Putative pharmacodynamics\u003c\/h4\u003e\n\u003cp data-end=\"2296\" data-start=\"2091\"\u003eBecause Adamax is a \u003cstrong data-end=\"2129\" data-start=\"2111\"\u003eSemax analogue\u003c\/strong\u003e, most mechanistic narratives are \u003cstrong data-end=\"2198\" data-start=\"2163\"\u003eextrapolated from Semax biology\u003c\/strong\u003e plus the expectation that “improved stability\/penetration” yields stronger or longer CNS effects.\u003c\/p\u003e\n\u003cp data-end=\"2548\" data-start=\"2298\"\u003eFor \u003cstrong data-end=\"2311\" data-start=\"2302\"\u003eSemax\u003c\/strong\u003e, transcriptomic work in rat focal brain ischemia reports that Semax \u003cstrong data-end=\"2409\" data-start=\"2380\"\u003emodulates gene expression\u003c\/strong\u003e, including immune-response–related genes and vascular-system–related processes in the injured brain. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"2633\" data-start=\"2550\"\u003e\u003cstrong data-end=\"2576\" data-start=\"2550\"\u003eAdamax-specific claims\u003c\/strong\u003e (commonly stated in vendor\/secondary summaries) include:\u003c\/p\u003e\n\u003cul data-end=\"2778\" data-start=\"2634\"\u003e\n\u003cli data-end=\"2701\" data-start=\"2634\"\u003e\n\u003cp data-end=\"2701\" data-start=\"2636\"\u003e↑ \u003cstrong data-end=\"2646\" data-start=\"2638\"\u003eBDNF\u003c\/strong\u003e signaling and\/or ↑ \u003cstrong data-end=\"2686\" data-start=\"2666\"\u003eTrkB sensitivity\u003c\/strong\u003e (hippocampus),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2738\" data-start=\"2702\"\u003e\n\u003cp data-end=\"2738\" data-start=\"2704\"\u003ecognitive\/mood resilience effects,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2778\" data-start=\"2739\"\u003e\n\u003cp data-end=\"2778\" data-start=\"2741\"\u003eenhanced physical endurance\/recovery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3013\" data-start=\"2780\"\u003eThese claims are \u003cstrong data-end=\"2869\" data-start=\"2797\"\u003enot well anchored to high-quality, peer-reviewed Adamax human trials\u003c\/strong\u003e in the sources surfaced here, so they should be treated as \u003cstrong data-end=\"2964\" data-start=\"2929\"\u003ehypotheses\/marketing assertions\u003c\/strong\u003e unless you can cite primary experimental papers.\u003c\/p\u003e\n\u003chr data-end=\"3018\" data-start=\"3015\"\u003e\n\u003ch3 data-end=\"3071\" data-start=\"3020\"\u003e4) Pharmacokinetics and delivery considerations\u003c\/h3\u003e\n\u003cp data-end=\"3211\" data-start=\"3072\"\u003eThere is \u003cstrong data-end=\"3101\" data-start=\"3081\"\u003eno drug-label PK\u003c\/strong\u003e for Adamax, and robust PK parameters (t½, bioavailability, CSF\/brain exposure) are not publicly standardized.\u003c\/p\u003e\n\u003cp data-end=\"3260\" data-start=\"3213\"\u003eGeneral peptide principles that \u003cem data-end=\"3253\" data-start=\"3245\"\u003elikely\u003c\/em\u003e apply:\u003c\/p\u003e\n\u003cul data-end=\"3691\" data-start=\"3261\"\u003e\n\u003cli data-end=\"3340\" data-start=\"3261\"\u003e\n\u003cp data-end=\"3340\" data-start=\"3263\"\u003e\u003cstrong data-end=\"3283\" data-start=\"3263\"\u003eTerminal capping\u003c\/strong\u003e (Ac- \/ -NH₂) can improve stability vs uncapped peptides.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3443\" data-start=\"3341\"\u003e\n\u003cp data-end=\"3443\" data-start=\"3343\"\u003eAny \u003cstrong data-end=\"3360\" data-start=\"3347\"\u003eadamantyl\u003c\/strong\u003e substitution can increase lipophilicity and potentially alter tissue distribution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3691\" data-start=\"3444\"\u003e\n\u003cp data-end=\"3691\" data-start=\"3446\"\u003e\u003cstrong data-end=\"3463\" data-start=\"3446\"\u003eRoute matters\u003c\/strong\u003e: Adamax is frequently marketed as \u003cstrong data-end=\"3518\" data-start=\"3498\"\u003eintranasal spray\u003c\/strong\u003e in consumer channels, which—if real product identity\/purity were controlled—could theoretically favor CNS exposure; however, this is not a substitute for formal PK\/PD data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3696\" data-start=\"3693\"\u003e\n\u003ch3 data-end=\"3747\" data-start=\"3698\"\u003e5) Evidence base (what’s solid vs what’s not)\u003c\/h3\u003e\n\u003ch4 data-end=\"3782\" data-start=\"3749\"\u003e5.1 Stronger anchor evidence\u003c\/h4\u003e\n\u003cul data-end=\"4312\" data-start=\"3783\"\u003e\n\u003cli data-end=\"3923\" data-start=\"3783\"\u003e\n\u003cp data-end=\"3923\" data-start=\"3785\"\u003e\u003cstrong data-end=\"3817\" data-start=\"3785\"\u003eSemax mechanistic literature\u003c\/strong\u003e: gene-expression modulation in brain injury models (preclinical). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4121\" data-start=\"3924\"\u003e\n\u003cp data-end=\"4121\" data-start=\"3926\"\u003e\u003cstrong data-end=\"3954\" data-start=\"3926\"\u003eRegulatory documentation\u003c\/strong\u003e: Medsafe explicitly discusses Adamax\/Semax among “unscheduled peptides” and ACTH analogues marketed for cognitive enhancement. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4312\" data-start=\"4122\"\u003e\n\u003cp data-end=\"4312\" data-start=\"4124\"\u003e\u003cstrong data-end=\"4154\" data-start=\"4124\"\u003eIdentity\/sequence listings\u003c\/strong\u003e: multiple chemical\/vendor databases list the Adamax sequence (Ac-MEHFPGPAG; and variants including adamantyl notation). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-end=\"4369\" data-start=\"4314\"\u003e5.2 What is not established (high-confidence gaps)\u003c\/h4\u003e\n\u003cul data-end=\"4558\" data-start=\"4370\"\u003e\n\u003cli data-end=\"4449\" data-start=\"4370\"\u003e\n\u003cp data-end=\"4449\" data-start=\"4372\"\u003eWell-powered \u003cstrong data-end=\"4399\" data-start=\"4385\"\u003ehuman RCTs\u003c\/strong\u003e showing clinically meaningful cognitive outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4503\" data-start=\"4450\"\u003e\n\u003cp data-end=\"4503\" data-start=\"4452\"\u003eStandardized \u003cstrong data-end=\"4487\" data-start=\"4465\"\u003ePK\/BBB penetration\u003c\/strong\u003e data in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4558\" data-start=\"4504\"\u003e\n\u003cp data-end=\"4558\" data-start=\"4506\"\u003eComprehensive \u003cstrong data-end=\"4548\" data-start=\"4520\"\u003esafety\/pharmacovigilance\u003c\/strong\u003e datasets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4563\" data-start=\"4560\"\u003e\n\u003ch3 data-end=\"4619\" data-start=\"4565\"\u003e6) Safety and tolerability (risk-based assessment)\u003c\/h3\u003e\n\u003cp data-end=\"4777\" data-start=\"4620\"\u003eBecause Adamax is typically sold outside approved pharmaceutical channels, the dominant risks are often \u003cstrong data-end=\"4753\" data-start=\"4724\"\u003eproduct and route related\u003c\/strong\u003e, not just pharmacology:\u003c\/p\u003e\n\u003cul data-end=\"5324\" data-start=\"4779\"\u003e\n\u003cli data-end=\"4941\" data-start=\"4779\"\u003e\n\u003cp data-end=\"4941\" data-start=\"4781\"\u003e\u003cstrong data-end=\"4812\" data-start=\"4781\"\u003eIdentity\/purity variability\u003c\/strong\u003e: sequence notation differences and inconsistent marketing claims are common; this increases risk of adulteration or mislabeling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5044\" data-start=\"4942\"\u003e\n\u003cp data-end=\"5044\" data-start=\"4944\"\u003e\u003cstrong data-end=\"4962\" data-start=\"4944\"\u003eSterility risk\u003c\/strong\u003e: particularly relevant if products are administered intranasally or by injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5226\" data-start=\"5045\"\u003e\n\u003cp data-end=\"5226\" data-start=\"5047\"\u003e\u003cstrong data-end=\"5072\" data-start=\"5047\"\u003eUnknown dose–response\u003c\/strong\u003e in humans: without controlled trials, adverse neuropsychiatric effects, blood pressure\/HR effects, or idiosyncratic reactions cannot be reliably bounded.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5324\" data-start=\"5227\"\u003e\n\u003cp data-end=\"5324\" data-start=\"5229\"\u003e\u003cstrong data-end=\"5252\" data-start=\"5229\"\u003ePeptide class risks\u003c\/strong\u003e: potential hypersensitivity reactions and excipient-related irritation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5329\" data-start=\"5326\"\u003e\n\u003ch3 data-end=\"5358\" data-start=\"5331\"\u003e7) Regulatory landscape\u003c\/h3\u003e\n\u003cul data-end=\"5581\" data-start=\"5359\"\u003e\n\u003cli data-end=\"5400\" data-start=\"5359\"\u003e\n\u003cp data-end=\"5400\" data-start=\"5361\"\u003e\u003cstrong data-end=\"5385\" data-start=\"5361\"\u003eNot FDA\/EMA-approved\u003c\/strong\u003e as a medicine.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5581\" data-start=\"5401\"\u003e\n\u003cp data-end=\"5581\" data-start=\"5403\"\u003eMedsafe has explicitly discussed Adamax within proposed peptide classification frameworks and notes it has appeared in enforcement contexts. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5586\" data-start=\"5583\"\u003e\n\u003ch3 data-end=\"5659\" data-start=\"5588\"\u003e8) Future directions (what would make Adamax scientifically “real”)\u003c\/h3\u003e\n\u003cp data-end=\"5735\" data-start=\"5660\"\u003eIf Adamax were to be evaluated to modern standards, the key steps would be:\u003c\/p\u003e\n\u003col data-end=\"6113\" data-start=\"5736\"\u003e\n\u003cli data-end=\"5843\" data-start=\"5736\"\u003e\n\u003cp data-end=\"5843\" data-start=\"5739\"\u003e\u003cstrong data-end=\"5778\" data-start=\"5739\"\u003eAnalytical identity standardization\u003c\/strong\u003e (MS\/HPLC; confirm adamantyl residue identity; impurity profile).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5970\" data-start=\"5844\"\u003e\n\u003cp data-end=\"5970\" data-start=\"5847\"\u003e\u003cstrong data-end=\"5864\" data-start=\"5847\"\u003ePK\/PD studies\u003c\/strong\u003e (including intranasal vs systemic, CSF\/brain exposure, and biomarkers like BDNF\/TrkB pathway engagement).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6113\" data-start=\"5971\"\u003e\n\u003cp data-end=\"6113\" data-start=\"5974\"\u003e\u003cstrong data-end=\"6004\" data-start=\"5974\"\u003eControlled clinical trials\u003c\/strong\u003e with validated endpoints (memory, attention\/executive function, mood\/stress scales), plus safety monitoring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"6118\" data-start=\"6115\"\u003e\n\u003ch3 data-end=\"6163\" data-start=\"6120\"\u003eSelected references (most load-bearing)\u003c\/h3\u003e\n\u003cul data-end=\"6797\" data-start=\"6164\"\u003e\n\u003cli data-end=\"6280\" data-start=\"6164\"\u003e\n\u003cp data-end=\"6280\" data-start=\"6166\"\u003eAdamax definition and relationship to Semax + P021 terminal modifications: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6448\" data-start=\"6281\"\u003e\n\u003cp data-end=\"6448\" data-start=\"6283\"\u003eMedsafe “Classification of Unscheduled Peptides” discussing Adamax\/Semax as ACTH analogues marketed as cognitive enhancers: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6555\" data-start=\"6449\"\u003e\n\u003cp data-end=\"6555\" data-start=\"6451\"\u003eMedsafe MCC minutes acknowledging peptide classification work: \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6687\" data-start=\"6556\"\u003e\n\u003cp data-end=\"6687\" data-start=\"6558\"\u003eSemax gene-expression effects in focal brain ischemia (preclinical mechanistic anchor): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6797\" data-start=\"6688\"\u003e\n\u003cp data-end=\"6797\" data-start=\"6690\"\u003eSequence listings for Adamax (Ac-MEHFPGPAG and related notation)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684841189714,"sku":null,"price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/adamax_10mg.png?v=1770834795","url":"https:\/\/sciencepeptideslab.com\/products\/adamax-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}